HOECHST-ROUSSEL REVISED INTERMITTENT CLAUDICATION INSTITUTIONAL AD
HOECHST-ROUSSEL REVISED INTERMITTENT CLAUDICATION INSTITUTIONAL AD for television will "increase public awareness of intermittent claudication and . . . advise the public to see their doctor -- but without implying that a prescription drug from Hoechst" (i.e., Trental is the remedy, FDA noted in a memo of a recent meeting between representatives from the firm and FDA's Rx Drug Advertising & Labeling Division. FDA's meeting with Hoechst followed an Aug. 19 letter to the firm objecting to its television ad on intermittent claudication. FDA had told the firm that the agency disagreed "with your contention that because 'there is no mention of the drug's name in this television advertisement,' it is an institutional ad and, thus need not comply with the advertising section of" the FD&C Act. FDA explained that "because of the emphasis it places on the availability of a drug for treating intermittent claudication, the commercial is, per se, at a minimum, an advertisement for a prescription drug." The memo states that "it was agreed that the proposed revision would be satisfactory if the language . . . were revised from 'And now there's effective treatment your doctor can prescribe' to something that says, essentially, 'And your doctor can prescribe an effective treatment program.' " FDA notified the firm in an Oct. 9 letter that it has "no objection to the revised message, as presented in story board form, for television presentation." The firm plans to air the revised ad in December. Noting that Hoechst intends "also to use the message in consumer print media in 1986," FDA stated that "for print media, since you are not limited to 30 seconds, we recommend that you expand on the meaning of 'effective treatment program,' e.g., smoking cessation, diet, exercise, etc." This recommendation was made for the TV message, FDA noted, "but withdrawn only because of time and space limitations."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth